Slipaid6 mg

Slipaid is a tricyclic antidepressant (TCA) of the dibenzoxepine class with established and evidence-based uses that differ by dose and formulation:

Established/FDA-approved uses

• Major depressive disorder (oral, standard/higher doses) — approved for treatment of depression in adults.
• Anxiety disorders (oral, standard doses) — approved for treatment of anxiety in adults, including anxiety associated with depression, alcohol use disorder, and certain psychophysiologic conditions.
• Insomnia characterized by difficulty with sleep maintenance — a very-low-dose oral formulation of Slipaid (3 mg/6 mg) is specifically FDA-approved for this indication in adults.
• Pruritus associated with atopic dermatitis or lichen simplex chronicus — a topical 5% cream formulation of Slipaid is FDA-approved for short-term relief of itching.

Off-label / adjunctive uses (commonly used, not FDA-approved indications)

• Chronic idiopathic urticaria (as an add-on when antihistamines alone are insufficient) — off-label, based on its potent H1/H2 antihistaminic activity.
• Chronic pain syndromes and neuropathic pain — off-label, extrapolated from TCA class evidence; requires individualized specialist assessment.

The specific indication and dose form must be determined by a physician; the low-dose insomnia formulation and higher-dose antidepressant formulation of Slipaid are not interchangeable.

Each dosage form of Doxepin contains Doxepin (as doxepin hydrochloride) as the active pharmaceutical ingredient. Doxepin is available in different strengths depending on the intended indication:

• Low-strength oral tablets (e.g., 3 mg, 6 mg) — for insomnia (sleep maintenance).
• Higher-strength oral capsules/tablets or oral concentrate solution (e.g., 10 mg, 25 mg, 50 mg, 75 mg, 100 mg) — for depression and anxiety.
• Topical cream (5%) — for short-term treatment of pruritus.

Inactive ingredients vary by manufacturer and formulation; refer to the specific product package insert for a complete list of excipients.

Slipaid is a tricyclic antidepressant (TCA) belonging to the dibenzoxepine chemical class. It works primarily by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin in the brain, which is believed to underlie its antidepressant and anxiolytic effects. At very low doses, Slipaid acts predominantly as a potent histamine H1-receptor antagonist, which is the basis for its use in sleep-maintenance insomnia and in pruritus.

Slipaid has been used clinically for decades and is available in oral (tablet/capsule/oral concentrate) and topical (cream) formulations, allowing it to be tailored to different indications ranging from major depression to itching associated with skin conditions.

Boxed Warning

Like other antidepressants, Slipaid carries a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25 years of age), particularly during the initial months of treatment or after dose changes. Patients started on Slipaid for depression should be monitored closely for worsening mood or emergence of suicidal ideation.

Slipaid belongs to the Tricyclic Antidepressants (TCAs) therapeutic class, specifically the dibenzoxepine subgroup. At low doses it is also classified functionally as a selective H1-antihistamine sedative-hypnotic used for insomnia.

Doxepin is a tricyclic compound that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuron, increasing their availability in the synaptic cleft. This is thought to underlie its antidepressant and anti-anxiety effects at standard-to-higher oral doses.

At very low doses (3 mg–6 mg), the dominant pharmacologic action of Doxepin is potent antagonism of histamine H1 receptors, without significant reuptake inhibition — this explains its selective sedative-hypnotic effect used for sleep maintenance insomnia, with minimal anticholinergic or cardiovascular impact at these doses.

Doxepin also has anticholinergic (antimuscarinic), antihistaminic (H1 and H2), and alpha-1 adrenergic blocking properties, which contribute to both its therapeutic uses (e.g., pruritus relief via H1/H2 blockade) and its characteristic side-effect profile (dry mouth, sedation, orthostatic hypotension).

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentration in 2–4 hours (higher doses) or somewhat delayed with food for the low-dose insomnia formulation.
• Metabolism: Hepatic, primarily via CYP2D6 and CYP1A2, to the active metabolite desmethyldoxepin (nordoxepin).
• Half-life: Approximately 15 hours (Doxepin) and up to 31 hours (desmethyldoxepin metabolite), allowing once-daily dosing.
• Excretion: Primarily renal, as metabolites/conjugates.

• Oral Slipaid (standard-dose capsules/tablets/concentrate) may be taken with or without food; the oral concentrate must be diluted in water, milk, or juice (not carbonated beverages) immediately before taking, as directed by the pharmacist/physician.
• The low-dose insomnia tablet formulation of Slipaid should be taken on an empty stomach, within 30 minutes of bedtime, and not within 3 hours of a meal.
• The topical cream formulation of Slipaid should be applied as a thin film to clean, dry, affected skin only; wash hands after application unless the hands are the treated area.
• Do not abruptly discontinue Slipaid after prolonged use; dose should be tapered gradually under medical supervision to avoid discontinuation symptoms.

Slipaid has several well-documented, clinically significant drug interactions:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use or use within 14 days of stopping an MAOI is contraindicated (see Contraindications) due to risk of hyperpyretic crisis, severe hypertension, and serotonin syndrome.
• CNS depressants (alcohol, benzodiazepines, opioids, sedative-hypnotics): Additive sedation and respiratory/CNS depression; this is particularly important with the low-dose insomnia formulation — avoid alcohol or other sedatives on the same night as dosing.
• Other anticholinergic drugs: Additive anticholinergic effects (severe constipation, urinary retention, confusion, blurred vision), especially in the elderly.
• CYP2D6/CYP1A2 inhibitors (e.g., cimetidine, fluoxetine, paroxetine): Can increase Slipaid plasma levels, raising the risk of toxicity (including cardiac and anticholinergic effects); dose adjustment of Slipaid may be needed.
• Other drugs that prolong the QT interval or affect cardiac conduction: Additive risk of arrhythmia when combined with Slipaid, particularly relevant in overdose or in patients with pre-existing cardiac disease.
• Sympathomimetic agents: Slipaid may alter (potentiate or block) the pressor response, requiring caution with concomitant use.

Side effects of Slipaid vary with dose and formulation.

Common (more likely at standard/higher antidepressant doses)

• Drowsiness/sedation
• Dry mouth
• Constipation
• Blurred vision
• Dizziness, orthostatic (postural) hypotension
• Weight gain
• Urinary hesitancy

Less common but serious

• Cardiac conduction changes/arrhythmia (risk increases with higher doses, pre-existing cardiac disease, or overdose)
• Confusion, especially in the elderly
• Seizures (rare)
• Worsening of depression or emergence of suicidal thoughts (see Boxed Warning; see Precautions)

Low-dose (insomnia) formulation

At the 3 mg/6 mg insomnia dose, Slipaid is generally well tolerated, with somnolence/sedation and nausea being the most commonly reported effects; anticholinergic and cardiovascular effects are minimal at this dose.

Topical formulation

Local application-site burning, stinging, and drowsiness (from systemic absorption) are the most commonly reported effects with the topical cream form of Slipaid.

Pregnancy

Adequate and well-controlled studies of Slipaid in pregnant women are lacking. Slipaid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision. Neonates exposed to tricyclic antidepressants like Slipaid late in the third trimester have, in some reports, developed symptoms consistent with withdrawal or adaptation (irritability, jitteriness, feeding difficulty, respiratory distress) — physicians should be informed of Slipaid use as delivery approaches.

Lactation

Slipaid is excreted in breast milk. There are case reports of sedation and respiratory depression in breastfed infants of mothers taking Slipaid. Because of this, breastfeeding is generally not recommended during Slipaid therapy unless a physician determines the benefit clearly outweighs the risk, with close monitoring of the infant for sedation, poor feeding, or breathing difficulty.

Use of Slipaid in pregnancy or lactation should always be individualized in consultation with a physician.

Boxed Warning — Suicidality

Slipaid, like all antidepressants, increases the risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25 years of age), especially during the first few months of treatment or after dose changes. Close monitoring for clinical worsening, agitation, or emergence of suicidal thoughts is required, particularly early in treatment.

Cardiac conduction abnormalities

As a tricyclic antidepressant, Slipaid (at standard/higher doses) can affect cardiac conduction (QT prolongation, arrhythmia risk). Use with caution in patients with pre-existing cardiac disease, and this risk is markedly increased in overdose (see Overdose).

Elderly patients

Elderly patients are more sensitive to the anticholinergic effects of Slipaid (confusion, urinary retention, constipation) and to sedation, which increases fall risk. Lower starting doses and slow titration are recommended (see Dosage).

Sedation and CNS effects

Slipaid can cause significant drowsiness, particularly at higher doses and with the low-dose insomnia formulation. Patients should avoid alcohol and other sedating substances, and should not drive or operate heavy machinery until they know how Slipaid affects them, and should ensure a full night is available for sleep when using the insomnia dose.

Glaucoma and urinary retention

Use with caution in patients with a history of urinary retention or predisposition to angle-closure glaucoma who do not meet the absolute contraindication threshold (see Contraindications).

Withdrawal

Abrupt discontinuation of Slipaid after prolonged use may cause discontinuation symptoms; taper gradually under medical supervision.

Overdose with Slipaid, particularly with the higher antidepressant-strength formulations, is a serious medical emergency due to the well-recognized cardiotoxicity and neurotoxicity of tricyclic antidepressants. Overdose can cause dangerous cardiac arrhythmias, severe hypotension, seizures, marked anticholinergic toxicity (agitation, hyperthermia, dilated pupils), respiratory depression, coma, and death, and effects can be delayed or prolonged.

If overdose with Slipaid is suspected, seek immediate emergency medical attention or contact a poison control center right away. Do not attempt to manage a suspected Slipaid overdose at home; cardiac monitoring and supportive care in a hospital setting are required.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Slipaid is not approved for the treatment of depression, anxiety, or insomnia in children or adolescents; safety and efficacy in this population have not been established for these indications. If an antidepressant is prescribed in this age group, the boxed warning regarding increased suicidality risk applies and requires close monitoring (see Precautions).

Elderly

Elderly patients are more susceptible to the sedative, anticholinergic, and hypotensive effects of Slipaid; lower starting doses (e.g., 3 mg for the insomnia formulation, or reduced antidepressant starting doses) and careful titration are recommended.

Hepatic impairment

Since Slipaid is hepatically metabolized, patients with liver impairment may need reduced doses and closer monitoring.

Renal impairment

No well-established formal dose-adjustment guideline exists; use with caution and clinical monitoring.

Cardiac disease

Use with caution in patients with pre-existing cardiac conduction abnormalities or arrhythmia history (see Precautions).

Duration of Slipaid therapy depends on the indication and clinical response, and should be determined by the prescribing physician:

• Depression/Anxiety: Typically continued for at least several months after symptom improvement to reduce relapse risk; long-term use is individualized and periodically reassessed.
• Insomnia (low-dose formulation): Duration is individualized based on response; long-term use should be periodically reassessed by the physician.
• Pruritus (topical): Limited to short-term use, generally up to 8 days per course, to minimize systemic absorption and sensitization risk.

Do not stop or extend Slipaid treatment on your own without consulting your physician.

Doxepin belongs to the Tricyclic Antidepressant (TCA) class, dibenzoxepine subgroup; at low doses it functions as a selective H1-antihistamine.

Doxepin inhibits presynaptic reuptake of norepinephrine and serotonin at standard-to-higher doses, increasing their synaptic availability (antidepressant/anxiolytic effect). At very low doses, its dominant action shifts to potent, selective histamine H1-receptor antagonism, producing a sedative-hypnotic effect used for sleep maintenance insomnia, along with H1/H2 antihistaminic activity relevant to its antipruritic effect.

C

Slipaid is not FDA-approved for use in children or adolescents for depression, anxiety, or insomnia; safety and efficacy for these uses have not been established in pediatric patients. Any antidepressant use in this age group carries the boxed warning for increased suicidality risk and requires close medical monitoring (see Precautions and Warnings).